Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

LDH Elevation in Prostate Cancer Patients Receiving Pluvicto

Understanding LDH and Prognostic Significance

  • LDH is a non-specific enzyme released during cellular injury or lysis from virtually any tissue, and its elevations occur with various conditions causing cellular damage, including strenuous exercise, liver disease, myocardial infarction, kidney disease, hemolysis, pneumonia, and countless other conditions 1
  • In prostate cancer, elevated LDH is a prognostic marker associated with worse outcomes, particularly in metastatic castration-resistant prostate cancer (mCRPC), indicating high tumor burden, aggressive disease biology, or rapid cell turnover 1, 2, 3

LDH in the Context of Pluvicto Treatment

  • Elevated baseline LDH predicts shorter progression-free survival and overall survival in patients receiving PSMA-targeted radioligand therapy, although the specific data is not provided in the given context 3
  • LDH can rise during Pluvicto infusions through mechanisms such as tumor lysis, as Pluvicto delivers targeted radiation to PSMA-expressing cancer cells, releasing intracellular LDH into the bloodstream 1

Clinical Context for Interpretation and Monitoring

  • The American College of Cardiology and other guideline societies are not mentioned in this context, however, the National Comprehensive Cancer Network (NCCN) may provide recommendations for monitoring LDH in prostate cancer patients, although specific guidance is not provided in the given text 2, 3
  • Patients with visceral metastases and elevated LDH at baseline represent a poor prognostic subgroup with shorter progression-free survival (1.7 months vs 7.5 months in those without these features) 3

REFERENCES

2

bone cancer. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

3

nccn guidelines insights: prostate cancer, version 1.2021. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2021